在阿尔茨海默氏病的发病过程中,对粉样β物种的形态和分子剖析
Zaida L Almeida1, Daniela C Vaz2,3,4,5, Rui M M Brito6
1Chemistry Department and Coimbra Chemistry Centre - Institute of Molecular Sciences (CQC-IMS), University of Coimbra, 3004-535, Coimbra, Portugal. zalmeida@qui.uc.pt.
Molecular neurobiology
|October 24, 2024
概括
阿尔茨海默病 (AD) 涉及复杂的神经病理,包括粉样质斑块和团. 新兴疗法针对这些病理和新型分子物种来对抗这种常见的痴呆症.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 是全球痴呆的主要原因,约有65%的痴呆患者患有这种疾病.
- 阿尔茨海默病神经病理的特征是粉样斑块和病理,导致神经元功能障碍和细胞死亡.
研究的目的:
- 提供阿尔茨海默病神经病理学的全面概述,重点关注粉样斑块分类和病理学.
- 描述粉样蛋白级联假设,聚合机制,以及参与AD病变发生的各种分子物种.
- 审查目前FDA批准的AD药物和新兴治疗策略,包括新药发现方法.
主要方法:
- 粉样β (Aβ) 种的详细表征,包括单体,二元体,三元体和各种聚合物形式.
- 审查有关AD神经病理学,生物标志物和治疗干预措施的现有文献.
- 对针对Aβ和tau病理的新型AD治疗的正在进行的临床试验的分析.
主要成果:
- 粉样质斑块的分类为扩散型,非核心型,密集型和紧型.
- 描述各种Aβ物种的形成和特征,从单体到纤维和斑块.
- 确定目前正在临床试验中的许多治疗策略,包括单克隆抗体,疫苗和分泌酶调节器.
结论:
- 了解Aβ的多种分子物种和聚合途径对于开发有效的AD疗法至关重要.
- 目前正在研究多种新的治疗策略,超越传统的治疗方法,以针对特定的分子机制.
- 新的药物发现方法,如多目标导向的配体,为解决阿尔茨海默病提供了有前途的途径.
更多相关视频
相关概念视频
Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K


